191 related articles for article (PubMed ID: 27177220)
1. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.
Liu H; Innamarato PP; Kodumudi K; Weber A; Nemoto S; Robinson JL; Crago G; McCardle T; Royster E; Sarnaik AA; Pilon-Thomas S
Oncotarget; 2016 Jun; 7(25):37893-37905. PubMed ID: 27177220
[TBL] [Abstract][Full Text] [Related]
2. A Novel
Zhang L; Du J; Song Q; Zhang C; Wu X
J Immunol Res; 2022; 2022():1178874. PubMed ID: 35155685
[TBL] [Abstract][Full Text] [Related]
3. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.
Liu H; Weber A; Morse J; Kodumudi K; Scott E; Mullinax J; Sarnaik AA; Pilon-Thomas S
PLoS One; 2018; 13(4):e0196033. PubMed ID: 29694419
[TBL] [Abstract][Full Text] [Related]
4. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.
Werthmöller N; Frey B; Wunderlich R; Fietkau R; Gaipl US
Cell Death Dis; 2015 May; 6(5):e1761. PubMed ID: 25973681
[TBL] [Abstract][Full Text] [Related]
5. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.
Toomey P; Kodumudi K; Weber A; Kuhn L; Moore E; Sarnaik AA; Pilon-Thomas S
PLoS One; 2013; 8(7):e68561. PubMed ID: 23874673
[TBL] [Abstract][Full Text] [Related]
6. Rose Bengal suppresses gastric cancer cell proliferation via apoptosis and inhibits nitric oxide formation in macrophages.
Zamani Taghizadeh Rabe S; Mousavi SH; Tabasi N; Rastin M; Zamani Taghizadeh Rabe S; Siadat Z; Mahmoudi M
J Immunotoxicol; 2014 Oct; 11(4):367-75. PubMed ID: 24575814
[TBL] [Abstract][Full Text] [Related]
7. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death.
Qin J; Kunda N; Qiao G; Calata JF; Pardiwala K; Prabhakar BS; Maker AV
Cell Death Dis; 2017 Feb; 8(2):e2584. PubMed ID: 28151483
[TBL] [Abstract][Full Text] [Related]
8. The effect of high mobility group box-1 protein on splenic dendritic cell maturation in rats.
Zhu XM; Yao YM; Liang HP; Xu S; Dong N; Yu Y; Sheng ZY
J Interferon Cytokine Res; 2009 Oct; 29(10):677-86. PubMed ID: 19642897
[TBL] [Abstract][Full Text] [Related]
9. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
Wallace A; LaRosa DF; Kapoor V; Sun J; Cheng G; Jassar A; Blouin A; Ching LM; Albelda SM
Cancer Res; 2007 Jul; 67(14):7011-9. PubMed ID: 17638914
[TBL] [Abstract][Full Text] [Related]
10. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.
Pan J; Zhang M; Wang J; Wang Q; Xia D; Sun W; Zhang L; Yu H; Cao X
J Cancer Res Clin Oncol; 2005 Jul; 131(7):468-78. PubMed ID: 15711825
[TBL] [Abstract][Full Text] [Related]
12. The antimetastatic activity of orlistat is accompanied by an antitumoral immune response in mouse melanoma.
de Almeida LY; Mariano FS; Bastos DC; Cavassani KA; Raphelson J; Mariano VS; Agostini M; Moreira FS; Coletta RD; Mattos-Graner RO; Graner E
Cancer Chemother Pharmacol; 2020 Feb; 85(2):321-330. PubMed ID: 31863126
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
15. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
16. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
[TBL] [Abstract][Full Text] [Related]
17. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
[TBL] [Abstract][Full Text] [Related]
19. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells.
Aguilera R; Saffie C; Tittarelli A; González FE; Ramírez M; Reyes D; Pereda C; Hevia D; García T; Salazar L; Ferreira A; Hermoso M; Mendoza-Naranjo A; Ferrada C; Garrido P; López MN; Salazar-Onfray F
Clin Cancer Res; 2011 Apr; 17(8):2474-83. PubMed ID: 21292818
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral injection of dendritic cells overexpressing interleukin‑12 inhibits melanoma growth.
Yao W; Li Y; Zeng L; Zhang X; Zhou Z; Zheng M; Wan H
Oncol Rep; 2019 Jul; 42(1):370-376. PubMed ID: 31115558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
